Get the latest tech news
DeepMind Spin-off Aims To Halve Drug Discovery Times Following Big Pharma Deals
The head of Google DeepMind believes its drug discovery spinout will halve the time taken to find new medicines, attracting the attention of the world's biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process. From a report: Speaking to the ...
The head of Google DeepMind believes its drug discovery spinout will halve the time taken to find new medicines, attracting the attention of the world's biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process. Hassabis stated the goal days after announcing Isomorphic Lab's first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform the finances of the unprofitable group. Isomorphic Labs uses an AI platform to predict biochemical structures, which aids the creation of new drugs by recommending which potential compounds will have the desired impact in the body.
Or read this on Slashdot
